Health ❯ Healthcare ❯ Pharmaceuticals

Weight Loss

GLP-1 Drugs Wegovy GLP-1 Medications Mounjaro Obesity Treatments Semaglutide Obesity Treatment Orforglipron Clinical Trials GLP-1 Receptor Agonists

UK Regulator Approves Eli Lilly’s Foundayo Tablet for Weight Loss and Type 2 Diabetes

The MHRA’s authorisation allows private prescriptions now, with NHS funding subject to a NICE cost‑effectiveness review.

Retailers Move to Fill $50 Medicare GLP‑1 Prescriptions

European Commission Approves First Oral Semaglutide Pill for Weight Loss

GLP‑1 Use Reaches 11% of U.S. Adults as New Evidence Spurs Policy and Safety Scrutiny

Wegovy Pill Approved, Private Sales Start in UK

Superdrug Begins UK Sales of Wegovy Oral Weight‑Loss Tablets

MHRA Approves Wegovy Weight‑Loss Tablet as Private Demand Soars

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

Employers and Insurers Pull Back Coverage for GLP‑1 Weight‑Loss Drugs

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

UAE Becomes First Country Outside U.S. to Offer Wegovy Pill

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

New Data Link GLP-1 Weight-Loss Drugs to Fewer Sick Days and Lower Disease Risks

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

Novo Nordisk Lifts Outlook After Wegovy Pill Fuels Q1 Beat

CMS Pauses Medicare GLP-1 Pilot After Insurers Balk, Sets 2026–27 Bridge